Drug-induced supersensitivity psychosis revisited: Characteristics of relapse in treatment-compliant patients

Therapeutic Advances in Psychopharmacology

Volumn 2, Issue 1, 2012, Pages 13-22

  Fallon, Paul ^a   Dursun, Serdar ^a   Deakin, Bill ^a  

^a NONE

Author keywords

diagnostic checklist; relapse; supersensitivity psychosis

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DELUSION; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG INDUCED SUPERSENSITIVITY PSYCHOSIS; DYSKINESIA; FEMALE; HALLUCINATION; HUMAN; LIFE EVENT; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SUPERSENSITIVITY; THOUGHT DISORDER;

EID: 84998124991     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125311431105     Document Type: Article

References (19)

1. Atkins M. Burgess A. Bottomley C. Riccio M. (1997) Chlorpromazine equivalents: a consensus of opinion for both clinical and research implications. Psychiatr Bull 21: 224–226.
2. Bebbington P.E. Craig T. Garety P. Fowler D. Dunn G. Colbert S. et al. (2006) Remission and relapse in psychosis: operational definitions based on case-note data. Psychol Med 36: 1551–1562.
3. Bennett J. Done J. Hunt B. (1995) Assessing the side-effects of antipsychotic drugs: a survey of CPN practice. J Psychiatr Ment Health Nurs 2: 177–182.
4. Bentall R.P. Morrison A.P. (2002) More harm than good: the case against using antipsychotic drugs to prevent severe mental illness. J Ment Health 11: 351–356.
5. Briggs A. Wild D. Lees M. Reaney M. Dursun S. Parry D. et al. (2008) Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 6: 1–9.
6. Brown G.W. Harris T.O. (1978) Social Origins of Depression. London: Tavistock.
7. Chouinard G. (1990) Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 5: 21–33.
8. Chouinard G. Chouinard V.-A. (2008) Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 77: 69–77.
9. Drake R.J. Haley C.J. Akhtar S. Lewis S.W. (2000) Causes of duration of untreated psychosis in schizophrenia. Br J Psychiatry 177: 511–515.
10. Fallon P. Dursun S. (2011). A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J Psychopharmacol 25: 755–762.
11. Foster P. (1989) Neuroleptic equivalence. Pharm J 243: 431–432.
12. Hogarty G.E. Ulrich R.F. (1998) The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 32: 243–250.
13. Knable M.B. Heinz A. Raedler T. Weinberger D.R. (1997) Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res 75: 91–101.
14. Marland G.R. Sharkey V. (1999) Depot neuroleptics, schizophrenia and the role of the nurse: is practice evidence based? A review of the literature. J Adv Nurs 30: 1255–1262.
15. Van Os J. Fahy T.A. Bebbington P. Jones P. Wilkins S. Sham P. et al. (1994) The influence of life events on the subsequent course of psychotic illness: a prospective follow-up of the Camberwell Collaborative Psychosis Study. Psychol Med 24: 503–513.
16. Voruganti L. Cortese L. Oyewumi L. Cernovsky Z. Zirul S. Awad A. (2000) Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 43: 135–145.
17. Whittaker R. (2004) The case against antipsychotic drugs: a 50-year record of doing more harm than good. Med Hypotheses 62: 5–13.
18. WHO (1999) Schedules for Clinical Assessment in Neuropsychiatry. Geneva: World Health Organization.
19. Woods S.W. (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64: 663–667.